Stocks › INDV
Indivior Pharmaceuticals, Inc. (INDV) stock analysis
WEAK BUY 29% confidence · analysed Nov 2, 2026
On Nov 2, 2026, our model rated Indivior Pharmaceuticals, Inc. (INDV) WEAK BUY with 29% confidence at a price of $35.37. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 46, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above its 50-day moving average but still below the 200-day: a short-term recovery inside a longer-term downtrend.
Volume is 1.6x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $42.81 and the swing low is $27.68; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 32.8% and revenue growth of +13.4%.
In its latest quarter it earned $1.32 per share, which beat the $1.13 analysts expected, with revenue +13.6% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $49.50.
The next earnings report is expected around Feb 25, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $36.17, a target of $39.04 (+7.9%) and a stop-loss at $33.50 (-7.4%).
That is a reward-to-risk ratio of about 1.1 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 12, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.29 (WEAK BUY). Technicals: RSI 45.82, MACD bullish, price above SMA50. Fundamentals: margin 32.8%, revenue growth 13.4%. Financial results: YoY revenue +13.6%, last EPS surprise +16.8%, next earnings 2027-02-25. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block, price retesting a bearish order block. FinGPT news read: positive. Suggested levels: entry $36.17, target $39.04, stop-loss $33.5, exit by 2026-11-12 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for INDV
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 2, 2026 | WEAK BUY | 29% | $35.37 | — |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
IOVA · IRWD · JNJ · KMDA · KRYS · LEGN · LH · LLY · LQDA · MDT · MEDP · NRC
Frequently asked questions
Is INDV a buy right now?
As of Nov 2, 2026, our automated model rates Indivior Pharmaceuticals, Inc. (INDV) WEAK BUY with 29% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for INDV?
The model's most recent plan targets $39.04 with a stop-loss at $33.50, from an entry near $36.17.
When does Indivior Pharmaceuticals, Inc. report earnings next?
The next earnings report is expected around Feb 25, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.